Alexza Pharmaceuticals first-one fourth net loss raises to $13.

Alexza Pharmaceuticals first-one fourth net loss raises to $13.4 million Alexza Pharmaceuticals, Inc. today reported financial results for the initial quarter ended March 31, 2010 and supplied a business update.4 million and $6.9 million, respectively.0 million. Alexza Business Updates The following key events occurred because the start of the first quarter of 2010: Alexza founded its first collaboration for AZ-004 with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, for the Canada and US.Alexza received notification from the FDA that its AZ-004 NDA was accepted for filing and the PDUFA goal date is October 11, 2010.In May, Alexza executed a $15.0 million working capital loan agreement with Hercules Technology Development Capital.‘While increasing attention offers been paid to the general public health threat of prescription drug abuse, we also need to be familiar with the growing dangers of misuse of over-the-counter cough and cold medications, among young people especially,’ stated Terry Cline, the agency’s administrator.

Maganga, D.V.M., Ph.D., Jimmy Kapetshi, M.D., Nicolas Berthet, Pharm.D., Ph.D.D., Felix Kabange, M.D., Placide Mbala Kingebeni, M.D., Vital Mondonge, M.D., Jean-Jacques T. Muyembe, M.D., Ph.D., Eric Bertherat, M.D., Sylvie Briand, M.D., Joseph Cabore, M.D., Alain Epelboin, M.D., Pierre Formenty, D.V.M., M.P.H., Gary Kobinger, M.D.Sc., Ingrid Labouba, Ph.D., Jean-Claude Manuguerra, Ph.D., Jean-Marie Okwo-Bele, M.D., Christopher Dye, D.